ORPHA:423968
Squamous cell carcinoma of the small intestine
Also known as: Squamous cell carcinoma of the small bowel
Publications
54
42.3th percentile
Trials
1
Interventional, condition-specific
Researchers
330
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Squamous cell carcinoma of the small intestine is an extremely rare, malignant, epithelial tumor of the small intestine (most often localized in the duodenum). Presenting symptoms are often nonspecific, such as weight loss, epigastric pain, anorexia, weakness, fatigue, vomiting and abdominal distension, and vary depending on localization of the tumor. Gastrointestinal bleeding and perforation may occur in advanced cases.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018509
- UMLS:C1710111
- NCIT:C43534
Additional Mondo synonyms (4)
small intestinal squamous cell cancer · small intestinal squamous cell carcinoma · small intestine squamous cell carcinoma · squamous cell carcinoma of the small bowel
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
54 matched papers (33 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
54
54 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
54 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
33 in the last 10 years · high confidence · 42.3th percentile (publications denominator)
Phrase hits: 54 · MeSH hits: 0
Who's working on it?
330
Distinct author names in 54 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang S3 papers · 2021
Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China.
Papers in Europe PMC - 02Wang Y3 papers · 2025
Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China.
Papers in Europe PMC - 03Zhang Y3 papers · 2026
Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Papers in Europe PMC - 04Ji X2 papers · 2023
Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Hospital Chinese Academy of Medical Sciences, Chaoyang District, Beijing, China.
Papers in Europe PMC - 05Khushman M2 papers · 2021
Medical Oncology, The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, USA.
Papers in Europe PMC - 06Kikuchi H2 papers · 1994Papers in Europe PMC
- 07Kitamura N2 papers · 1994Papers in Europe PMC
- 08Liu H2 papers · 2021
Department of Pharmacology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Papers in Europe PMC - 09Nakayoshi A2 papers · 1994
Department of Surgery, Showa University Fujigaoka Hospital.
Papers in Europe PMC - 10Namatame K2 papers · 1994Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 2,555 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
high confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: squamous cell carcinoma
2,555
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 29 · after dedupe 29 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 29 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (29)
- isrctn·ISRCTN55168173·No longer recruiting·Testing a potential new treatment for patients with severe alcohol-associated hepatitis called SZN-043
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10010669·No longer recruiting·A study to assess the effect of tiragolumab in presence of atezolizumab and bevacizumab in participants detected with lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16847938·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body and mechanism of action of RO7486967 in participants with ulcerative colitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97547683·No longer recruiting·Treg Immunotherapy in Crohn’s Disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN67919733·No longer recruiting·A randomised controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14753723·Recruiting·A study to test the safety, tolerability and effect of ZI-MA4-1 for patients with locally advanced or metastatic solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78284158·No longer recruiting·Heated intraperitoneal chemotherapy for the treatment of primary ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65855590·Recruiting·Bivalent vaccination against Salmonella Typhi and Paratyphi A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15046526·Recruiting·A platform trial for patients with relapsed malignant mesothelioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28447330·No longer recruiting·WHiTE13-DECI: An investigation of people 60 years and over with a broken hip to determine whether they are less likely to have delirium after hip surgery if we treat them with infliximab during the operation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11391038·No longer recruiting·Darovasertib is being used in comparison to crizotinib versus investigators' choice of treatment for negative (no specific marker) in this rare type of eye cancer which has been spread to other parts of the body, beyond the eye.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31763161·Stopped·A study to test the safety and immune response in adult humans of a new vaccine against four different types of Shigella bacteria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14903256·No longer recruiting·Study of the efficacy and safety of parsaclisib in participants with primary warm autoimmune hemolytic anemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79243381·No longer recruiting·Investigating a vaccine against plague in Uganda (PlaVac Uganda)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16171129·No longer recruiting·A randomised Phase II trial to assess whether niraparib is beneficial in patients with mesothelioma that has progressed and been previously treated when compared to the standard of care treatment, termed active symptom control
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62420110·No longer recruiting·A study of selicrelumab (RO7009789) in combination with atezolizumab in participants with locally advanced and/or metastatic solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36344989·Recruiting·PEARLS - a trial of radiotherapy in newly-diagnosed patients with lymph node positive prostate cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35774409·No longer recruiting·A study to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of RO7009789 (selicrelumab) in combination with vanucizumab or bevacizumab in patients with metastatic solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10639376·No longer recruiting·A trial looking at whether stereotactic radiotherapy together with chemotherapy is a useful treatment for people with locally advanced bile duct cancer (ABC-07)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10760016·No longer recruiting·A study of the drugs AZD2014 and rituximab in relapsed or refractory diffuse large B-cell lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38344105·No longer recruiting·National Lung Matrix Trial: multi-drug phase II trial in non-small cell (NSC) lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11233255·No longer recruiting·BUTEO: a clinical trial of BTT1023 in patients with primary sclerosing cholangitis (PSC)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the small intestine — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the small intestine" OR "Squamous cell carcinoma of small intestine" OR "Squamous cell carcinoma of the small bowel" OR "Squamous cell carcinoma of small bowel" OR "small intestinal squamous cell cancer" OR "small intestinal squamous cell carcinoma" OR "small intestine squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the small intestine" OR "Squamous cell carcinoma of small intestine" OR "Squamous cell carcinoma of the small bowel" OR "Squamous cell carcinoma of small bowel" OR "small intestinal squamous cell cancer" OR "small intestinal squamous cell carcinoma" OR "small intestine squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:53:50.545Z
